11/20
04:30 am
hcm
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
Low
Report
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
11/19
12:09 am
hcm
HUTCHMED (China) Limited (NASDAQ: HCM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
HUTCHMED (China) Limited (NASDAQ: HCM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/5
11:00 pm
hcm
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
Low
Report
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
11/4
11:14 pm
hcm
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
10/31
04:38 am
hcm
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda [Yahoo! Finance]
Medium
Report
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda [Yahoo! Finance]
10/31
04:30 am
hcm
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
Medium
Report
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
10/16
12:30 am
hcm
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
Medium
Report
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
9/24
03:00 am
hcm
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
Medium
Report
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
9/8
08:00 pm
hcm
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
Low
Report
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
8/30
12:33 am
hcm
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China [Yahoo! Finance]
Medium
Report
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China [Yahoo! Finance]
8/30
12:30 am
hcm
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
Medium
Report
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China